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Abstract: Pomegranate (Punica granatum) is a well-established folklore medicine, demonstrating benefits
in treating numerous conditions partly due to its antimicrobial and anti-inflammatory properties.
Such desirable medicinal capabilities are attributed to a high hydrolysable tannin content, especially
punicalagin. However, few studies have evaluated the abilities of pomegranate to promote oral healing,
during situations such as periodontal disease or trauma. Therefore, this study evaluated the antioxidant
and in vitro gingival wound healing effects of pomegranate rind extract (PRE) and punicalagin, alone
and in combination with Zn (II). In vitro antioxidant activities were studied using DPPH and ABTS
assays, with total PRE phenolic content measured by Folin–Ciocalteu assay. PRE, punicalagin and
Zn (II) combination effects on human gingival fibroblast viability/proliferation and migration were
investigated by MTT assay and scratch wounds, respectively. Punicalagin demonstrated superior
antioxidant capacities to PRE, although Zn (II) exerted no additional influences. PRE, punicalagin and
Zn (II) reduced gingival fibroblast viability and migration at high concentrations, but retained viability
at lower concentrations without Zn (II). Fibroblast speed and distance travelled during migration were
also enhanced by punicalagin with Zn (II) at low concentrations. Therefore, punicalagin in combination
with Zn (II) may promote certain anti-inflammatory and fibroblast responses to aid oral healing.
Keywords: pomegranate; punicalagin; tannins; gingiva; fibroblasts; antioxidant; wound healing
1. Introduction
Wound healing is a complex process, involving a chain of well-orchestrated biochemical and
cellular events that effect the repair of diseased or damaged tissues. Healing is mainly achieved through
four precise and programmed phases: homeostasis, inflammation, proliferation and remodeling.
These phases must occur in an orderly and suitable timeframe which is essential to normal healing,
although disruption to these mechanisms by various factors may cause delayed or non-healing to
occur [1].
Wounds within the oral cavity can be caused by many factors, including trauma, periodontal
disease and surgery. Although the oral cavity harbors a wide variety of commensal microbial
species [2], its distinct environment with continuous salivary flow helps prevent contamination and
infection [3,4]. Furthermore, although oral and dermal wounds proceed through similar stages of
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healing, oral wounds are characterized by rapid healing with minimal scar formation, mediated in
part via enhanced fibroblast and keratinocyte repair responses [5,6]. However, despite such superior
healing properties, oral wounds are common and yet difficult to protect using conventional wound
dressing approaches; and therefore are susceptible to microbial contamination and further trauma,
such as during mastication [7]. For the treatment of the oral wounds, antibiotics, corticosteroids,
non-steroidal anti-inflammatory drugs (NSAIDs) and disinfectants, such as chlorhexidine, have
all been used to accelerate the healing process and prevent patient disconformity [8]. However,
these drugs are commonly associated with various side effects, such as gastrointestinal damage,
discoloration, dysgeusia and excessive sensitivity in the oral mucosa [9]. Therefore, alternative
pharmaceutical therapies are needed for the promotion of oral wound healing, which overcome these
issues. Natural compounds and formulations may offer such promise, as many have had strong
historical roles in the treatment of many different diseases and conditions worldwide. As a result,
natural products are favored by modern societies and consumer acceptance is high [10,11]. Indeed,
it has been suggested that medicinal plants have more efficacious healing properties and less adverse
effects than the other more synthetic pharmaceutical chemicals [12,13].
Pomegranate (Punica granatum), a part of the punicaceae family native to the Middle East, is a
well-established folklore medicine, and mainly cultivated in Iran, India, USA and most of the near and far
eastern countries. It has been used in the treatment of dysentery, diarrhoea and stomatitis in traditional
medicine in many cultures which is documented in Egyptian Papyrus of Ebers [14,15]. Recent studies
have shown that pomegranate demonstrates benefits in treating numerous conditions, due to its
anticancer, antimicrobial, anti-inflammatory and antioxidant properties [16]. The different parts of
the pomegranate have rich sources of secondary metabolites with potential biological activities [17].
The fruit exocarp (rind) is particularly abundant in hydrolysable tannins, in particular punicalagin,
which is a large (mw 1,084.71 g/mol) molecule comprised of gallagic acid and ellagic acid linked via
a glucose moiety (Figure 1) [18,19]. These compounds have been attributed as being the primary
sources of bioactivity responsible for the desirable medicinal properties of pomegranate, including
their dermal wound healing efficacies [19–24]. Indeed, from our previous work, pomegranate rind
extract (PRE) and punicalagin itself have been shown to exhibit potent anti-inflammatory, antimicrobial
and antiviral activities, which can be further potentiated by combination with Zn (II) ions [25–28].
Zn (II) itself also has a prominent role in all stages of wound repair, regulating immuno-inflammatory
cell, endothelial cell, keratinocyte and fibroblast responses [29,30]. Indeed, the importance of Zn (II) to
successful wound repair outcomes is supported by studies correlating delayed healing with deficient
Zn (II) levels and enhanced repair following the topical application of Zn-containing compounds.
Thus, it may be hypothesized that PRE and punicalagin supplementation with Zn (II) can promote
additional beneficial wound healing effects. However, whereas beneficial PRE and punicalagin effects
on dermal wound healing are supported in the literature, no studies have to date examined whether
PRE and punicalagin could offer similar therapeutic wound healing benefits within the oral cavity.
Therefore, the purpose of the present study was to evaluate the potential of PRE and punicalagin,
with and without Zn (II), used to promote the healing of oral wounds caused by periodontal disease
or trauma. Specifically, PRE, punicalagin, Zn (II) alone and Zn (II) in combination with PRE and
punicalagin were assessed for their in vitro antioxidant activities, in addition to their effects on the
viability, proliferation and migration of human primary gingival fibroblasts.
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(DPPH), Folin–Ciocalteu (F-C) reagent, potassium persulphate, (±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox); dimethylsulfoxide (DMSO), ascorbic acid and 
sodium carbonate (Na2CO3) were all obtained from Sigma-Aldrich (Gillingham, UK). Zinc sulfate 
heptahydrate (ZnSO4.7H2O), potassium hydrogen phthalate, Dulbecco’s Modified Eagle Medium 
(DMEM), fetal calf serum (FCS), L-glutamine and antibiotics/antimycotics were obtained from 
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The net weight of the rind was 300 g. This was blended (25%) w/v in deionized water in a standard 
blender until visibly homogenous. The blended rind in deionized water was boiled for 10 min and 
centrifuged (×4) using a Heraeus Multifuge 3S/3S-R centrifuge (5980 g at 4 ℃ for 30 min), before 
filtration through a Whatman 0.45 µm nylon membrane filter. The collected solution was freeze dried, 
protected from light and stored at −20 ℃  until required. The desired concentration of PRE was 
prepared in pH 4.5 phthalate buffer and sterilized by using a 0.45 m Millex-FG syringe-driven filter 
[26]. Punicalagin concentrations were determined by HPLC (Thermo LCQ classic LCMS with ESI 
source) according to method of Seeram et al. [31]; and found that 1 mg/mL PRE contains 
approximately 17 g punicalagin. 
2.3. Determination of Total Phenolic Content 
The Folin–Ciocalteu (F-C) colorimetric assay was used to quantify the total phenolic content in 
PRE, according to method by Ainsworth and Gillespie [32]. Briefly, 0.5 mg/mL PRE samples were 
prepared and 200 L 10% (v/v) F-C reagent was added to 100 L of the prepared PRE samples, 
followed by the addition of 800 L 700 mM Na2CO3. Samples were incubated at room temperature 
for 2 h. After the incubation period, 200 L of each sample was added to 96-well plates and the 
absorbance values read at 760 nm on a plate reader (Fluostar Optima, BMG Labtech, Aylesbury, UK). 
The concentration of phenolic compounds in the PRE was shown as tannic acid equivalents (TAE) 
per gram of freeze-dried sample. 
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2.1. aterials
Pomegranates were obtained from a local supermarket and were of Spanish origin.
Punicalagin (≥98%), [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide] (MTT), 2,2′-azino-
bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt (ABTS), 2,2-diphenyl-1-picrylhydrazyl
(DPPH), Folin–Ciocalteu (F-C) reagent, potassium persulphate, (±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (Trolox); dimethylsulfoxide (DMSO), ascorbic acid and sodium
carbonate (Na2CO3) were all obtained from Sigma-Aldrich (Gillingham, UK). Zinc sulfate heptahydrate
(ZnSO4·7H2O), potassium hydrogen phthalate, Dulbecco’s Modified Eagle Medium (DMEM), fetal calf
serum (FCS), L-glutamine and antibiotics/antimycotics were obtained from ThermoFisher Scientific
(Loughborough, UK).
2.2. Preparation of Pomegranate Rind Extract (PRE)
The rind of the pomegranates was peeled with a scalpel and cut to approximately 2 cm2 pieces.
The net weight of the rind was 300 g. This was blended (25%) w/v in deionized water in a standard
blender until visibly homogenous. The blended rind in deionized water was boiled for 10 min and
centrifuged (×4) using a Heraeus Multifuge 3S/3S-R centrifuge (5980× g at 4 ◦C for 30 min), before
filtration through a Whatman 0.45 µm nylon membrane filter. The collected solution was freeze
dried, protected from light and stored at −20 ◦C until required. The desired concentration of PRE
was prepared in pH 4.5 phthalate buffer and sterilized by using a 0.45 µm Millex-FG syringe-driven
filter [26]. Punicalagin concentrations were determined by HPLC (Thermo LCQ classic LCMS with ESI
source) according to method of Seeram et al. [31]; and found that 1 mg/mL PRE contains approximately
17 µg punicalagin.
2.3. Determination of Total Phenolic Content
The Folin–Ciocalteu (F-C) colorimetric assay was used to quantify the total phenolic content
in PRE, according to method by Ainsworth and Gillespie [32]. Briefly, 0.5 mg/mL PRE samples
were prepared and 200 µL 10% (v/v) F-C reagent was added to 100 µL of the prepared PRE samples,
followed by the addition of 800 µL 700 mM Na2CO3. Samples were incubated at room temperature
for 2 h. After the incubation period, 200 µL of each sample was added to 96-well plates and the
absorbance values read at 760 nm on a plate reader (Fluostar Optima, BMG Labtech, Aylesbury, UK).
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The concentration of phenolic compounds in the PRE was shown as tannic acid equivalents (TAE) per
gram of freeze-dried sample.
2.4. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) Radical Scavenging Assay
The DPPH assay was used to evaluate the scavenging of stable radicals by PRE, punicalagin,
Zn (II) and PRE and punicalagin in combination with Zn (II), as previously described [33]. Briefly,
samples were initially prepared in 0.2 mM DPPH solution and two-fold serial dilutions made in 96-well
plates for each sample. Plates were wrapped in foil and incubated for 30 min at room temperature.
After 30 min, the absorbance values of each sample were read at 515 nm as above, versus samples
containing only DPPH (negative control), with ascorbic acid used as a positive control. The % of the
radical scavenging activities of each sample was calculated as follows:
% DPPH scavenging = 100 × [1 − (ODsample/ODcontrol)
The concentration of each sample which scavenged 50% of the initial DPPH radicals generated
was calculated by interpolating the [(Abs of the sample) − (Abs sample blank)] into a calibration
curve generated by the DPPH absorbance values at different sample concentrations. All assays were
performed on 3 separate occasions, with each experiment including 3 replicates.
2.5. The 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic-acid (ABTS) Radical Scavenging Assay/Trolox
Equivalent Antioxidant Activity (TEAC)
The antioxidant potential of PRE, punicalagin, Zn (II) and PRE and punicalagin in combination
with Zn (II), was also assessed using the ABTS/TEAC assay, based on the study by Re et al. [34].
This assay is based on the ability of compounds to scavenge the ABTS radical, produced by the
reaction between 7 mM ABTS and 2.45 mM potassium persulphate. The ABTS solution was prepared
and diluted to a final absorbance of 0.7 ± 0.2 at 734 nm obtained using a plate reader, as described
above. The antioxidant capacities of PRE and punicalagin (both 0.5 mg/mL) and 0.1 mM Zn (II) were
determined. Trolox (0–400 µg/mL) was used as a positive control and to express the data as Trolox
equivalent antioxidant capacity (TEAC). All assays were performed on 3 separate occasions, with each
experiment including 3 replicates.
2.6. Cell Culture
Human primary gingival fibroblasts were obtained from the American Type Cell Culture Collection
(ATCC, Manassas, VA, USA). Gingival fibroblasts were cultured in DMEM supplemented with 10%
heat-inactivated FCS, 1% L-glutamine (2 mM) and 1% antibiotic/antimycotic solution. Cells were
incubated at 37 ◦C in a humidified atmosphere of 5 % CO2. The passage number of cells used in all
experiments was between 2 and 7.
Samples were prepared fresh on the day of treatment. Different concentrations of PRE
(0.1–100 µg/mL), punicalagin (0.1–10 µg/mL), ZnSO4.7H2O (0.1 mM) and PRE and ZnSO4·7H2O
(0.1 mM), punicalagin and ZnSO4·7H2O (0.1 mM) were prepared. Freeze-dried PRE, Zn (II) and
punicalagin were firstly dissolved in phthalate buffer pH 4.5 to make the stock solutions, and then filtered
using 0.2 µm Minisart syringe filters made of acrylic resin, methacrylate butadiene styrene (Sartorius
Stedim Biotech GmbH, Göttingen, Germany), under sterile conditions. Compound concentrations
were further prepared in DMEM containing 1% FCS, 1% L-glutamine and 1% antibiotics/antimycotics.
Control culture medium was also supplemented with 1% phthalate buffer pH 4.5 to negate any
influences on cellular activities by the buffer itself.
2.7. Cell Viability and Proliferation
The effects of PRE, punicalagin, Zn (II) and PRE and punicalagin in combination with Zn (II) on
gingival fibroblast viability and proliferation were determined MTT assay [35]. Gingival fibroblasts
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were seeded into 96-well plates at a density of 2.5 × 103 cells/well and cultured at 37 ◦C/5% CO2 for
24 h. After 24 h, the media was changed to serum-free DMEM and the cells cultured for a further 24 h.
Cells were subsequently treated with various concentrations of the samples for 24, 48 and 72 h, with
media changes every 24 h. At each time point, 25 µL MTT (5 mg/mL in phosphate buffered saline,
PBS) was added to each well and cultured at 37 ◦C/5% CO2 for 4 h. After 4 h incubation, the MTT was
discarded and each well treated with 100 µL pure DMSO, followed by further incubation at 37 ◦C/5%
CO2 for 30 min, with light protection. The absorbance values of each well were then read at 570 nm.
Sample effects on cell viability and proliferation were expressed as % viable cells versus untreated
controls, which were arbitrarily assigned a viability of 100%. All assays were performed on 3 separate
occasions, with each experiment including 6 replicates.
2.8. Cell Migration and Wound Repopulation
The effects of PRE, punicalagin, Zn (II) and PRE and punicalagin in combination with Zn (II),
on fibroblast migration were assessed for the ability to stimulate in vitro scratch wound repopulation,
as previously described [36]. Gingival fibroblasts were seeded into 24-well plates at a density of
2.5 × 104 cells/well and cultured at 37 ◦C/5% CO2 for 48 h. After 48 h, the media was changed to
serum-free DMEM and the cells cultured for a further 24 h. Serum-free DMEM was removed and
scratch wounds made using sterile pipettes. Fibroblasts were subsequently treated with different
concentrations of test sample, with untreated cells in serum-free media serving as negative controls.
Cell migration and wound repopulation were monitored by automated time-lapse microscopy, using
a Cell-IQ® Automated Cell Culture and Analysis System (Chip-Man Technologies Ltd., Tampere,
Finland), at 37 ◦C/5% CO2. Digital images taken every 20 min over a 48 h period, using Cell-IQ
Analyser™ Software, whilst ImageJ® Software (Version 1.49, https://imagej.nih.gov/ij/), were used to
quantify cell migration parameters, including: cell displacement (Td), overall velocity (Td/t), distance
travelled (Tt) and migratory speed (Tt/t). Each experiment was performed on 3 separate occasions,
with each experiment including 3 replicates.
2.9. Statistical Analysis
Data values were expressed as the average ± standard error of the mean (SEM). Statistical analysis
of antioxidant data was performed using the Duncan’s multiple range test. Statistical analysis of
gingival fibroblast viability, proliferation and migration was performed by one-way ANOVA with
Tukey’s multiple comparison post-test. Statistical analyses were performed using the GraphPad Prism,
Version 8.00 (GraphPad Software, San Diego, CA, USA). Significance was considered at p < 0.05.
3. Results
3.1. Total Phenolic Content
The quantitative determination of the total phenolic content of PRE was expressed in µg TAE per
g of freeze-dried PRE. The results showed that, on average, freeze-dried PRE contained 496 mg TAE/g.
3.2. Antioxidant Activities Using DPPH and ABTS Assays
The antioxidant capacities of PRE, punicalagin and their combination with 0.1 mM Zn (II) were
assessed using both the DPPH and ABTS assays (Figure 2). The results of the DPPH assay are expressed
as % of DPPH inhibition and IC50 values (the sample concentration needed to inhibit 50% of the initial
DPPH free radical flux). All samples studied showed a dose-dependent response in the % of free
DPPH inhibition. PRE (10.69 ± 0.44%) and PRE in combination with 0.1 mM Zn (II) (8.1 ± 0.27%) were
required at higher concentrations than the ascorbic acid positive controls (8.31 ± 0.64%), to induce 50%
inhibition. However, punicalagin (6.04 ± 0.29%) and its combination with 0.1 mM Zn (II) (6.99 ± 0.20%)
required lower concentrations than the ascorbic acid controls. While there was a slight difference
between the compounds and their Zn (II) combinations, no statistically significant differences were
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observed (p > 0.05). The ABTS assay showed similar patterns of antioxidant capabilities to the DPPH
assay. Punicalagin and punicalagin with 0.1 mM Zn (II) exhibited significantly higher TEAC values
than PRE and PRE with 0.1 mM Zn (II) (p < 0.001). Similarly, 0.1 mM Zn (II) addition did not cause any
significant change in the antioxidant scavenging activities of PRE or punicalagin (p > 0.05).
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( ) values obtained for each sample, based on the finding of the ABTS assay. Values are presented
as the mean ± SEM (n = 3). TEAC, Trolox equivalent antioxidant capacity. Values followed by the same
capital letter within the same column are not significantly different (p > 0.05) between the compounds
analyzed by Duncan’s multiple range test. * ND; not determined.
3.3. Effects on Gingival Fibroblast Viability and Proliferation
The effects of PRE, punicalagin, Zn (II) and PRE and punicalagin in combination with Zn (II) on
fibroblast viability and proliferation, were determined by MTT assay (Figure 3). According to the
data obtained, 1 mM Zn (II) significantly reduced fibroblast viability and proliferation at all time-
points (p < 0.001), while lower Zn (II) concentrations did not exhibit such decreases at 24 or 48 h
(p > 0.05). When fibroblasts were treated with PRE or punicalagin alone, both showed dose-dependent
decreases in cell viability from 24 h onwards, at the highest concentrations of PRE (100 µg/mL) and
punicalagin (10 µg/mL) examined (p < 0.001). In contrast, lower concentrations of neither PRE nor
punicalagin influenced cell viability, versus untreated negative controls (NC, p > 0.05). However,
PRE and punicalagin combined with 0.1 mM Zn (II) significantly reduced fibroblast viability (p < 0.001),
although treatment with 0.1 mM Zn (II) alone did not decrease viability (p > 0.05).
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Figure 3. Effects of PRE (0.1–10 µ / µ / L) and 28.76 µg/mL (0.1 mM) Zn
(I ) alone an i i ith Zn ( I), on human gingival fibroblast viability and proliferation
at 24, 48 and 72 h, as determined by MTT assay. Valu s are presented as the mean % ± SEM (n = 3).
Mean values with an “a” letter was significantly different than the untr ated negative controls (p< .001).
3.4. Effects on Gingival Fibroblast Migration and Wound Repopulation
The effects of PRE, punicalagin, Zn (II) and PRE and punicalagin in combination with Zn (II) on
fibroblast migration and wound repopulation were evaluated using the in vitro scratch wound assays,
with cell displacement (Td), overall velocity (Td/t), distance travelled (Tt) and the migratory speed (Tt/t)
of the gingival fibroblasts monitored. PRE (100 µg/mL) and punicalagin (10 µg/mL) reduced gingival
fibroblast migration and wound repopulation, significantly decreasing fibroblast speed compared to
untreated controls (p < 0.001, Figures 4 and 5). In contrast, lower PRE and punicalagin concentrations
increased the speed, cell displacement, overall velocity and distance travelled. However, no significant
differences in these cellular parameters were determined versus untreated controls (all p > 0.05).
Fibroblasts treated with 0.1 mM Zn (II) did not show any significant differences compared to
untreated controls (p > 0.05, Figures 4 and 6). However, the combination of 0.1 µg/mL punicalagin and
0.1 mM Zn (II) induced a significant increase in cell speed and distance travelled, versus untreated
controls (p < 0.001). Likewise, although there was a significant decrease in fibroblasts treated only
with punicalagin at the highest concentration (10 µg/mL), when combined with 0.1 mM Zn (II), this
inhibitory effect was not observed (p > 0.05).
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4. Discussion
In light of its folklore medicinal status, crude pomegranate extracts and its constituent compounds,
such as punicalagin, have received much biomedical attention given the considerable evidence
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supporting their efficacy against a wide range of diseases and conditions, ascribed to its various
anticancer, antimicrobial, anti-inflammatory and antioxidant bioactivities [16]. Although numerous
studies have previously endorsed the beneficial effects of PRE and punicalagin and advocated their
application in the treatment of impaired wound healing responses in skin [19–24], a clinical area which
has largely been overlook from a wound healing viewpoint are the potential abilities of PRE and
punicalagin within the oral cavity, when tissue damage is commonly caused by periodontal disease and
trauma. Indeed, periodontal diseases, comprising gingivitis and periodontitis, are regarded as being
the most common disease of mankind, leading to huge economic burdens for healthcare providers
worldwide [37]. As prevalence is also associated with risk factors such as age and diabetes, projections
estimate further escalations in incidence with ever-increasing age demographics and diabetic rates
worldwide. Although a wide array of therapeutic entities are available, these predominantly possess
antibiotic, antimicrobial or anti-inflammatory properties, thereby indirectly promoting periodontal
healing through the eradication of dental plaque/bacterial biofilm accumulation and/or the exacerbation
of chronic inflammatory responses [8,37]. Furthermore, despite the development of a plethora of
antibiotic and non-antibiotic-based drug delivery approaches to counteract microbial accumulation,
biofilm formation or the inflammation associated with periodontal disease, few agents have fully
progressed to routine clinical use [38,39]. Thus, in addition to addressing the side effects commonly
associated with such therapeutics, the development of efficacious pharmaceutical options with
established potent antimicrobial, anti-inflammatory and pro-healing properties, such as pomegranate,
could meet a significant clinical and public health need in reducing the prevalence and severity of such
conditions on a global scale.
The bioactivities of pomegranate extracts are generally attributed to its phenolic contents.
Although the whole fruit comprises a large number of phenolic compounds, including anthocyanins,
gallotannins, hydroxycinnamic acids, hydroxybenzoic acids and hydrolysable tannins. Compared to
other parts of the fruit, pomegranate rind is known to contain the highest levels of bioactive
polyphenolics, especially hydrolysable tannins such as punicalagin, which are responsible for the
antioxidant activities of the PRE [18,40–43]. Indeed, potent antioxidant activity could play an important
role in periodontal wound healing, as chronic inflammation, excessive reactive oxygen species (ROS)
production and oxidative stress are key contributors to the host connective tissue damage associated
with periodontal disease pathology [44,45]. In this study, it was shown that the total polyphenol content
of the aqueous extract of PRE was 496 mg TAE/g freeze dried pomegranate rind. This result is similar
to study by Malviya and Jha [46], who quantified the total polyphenol content of pomegranate rind
using different solvents and found that water extract had the highest value, 435 mg TAE/g pomegranate
rind. Furthermore, in this study, the antioxidant activity was evaluated using DPPH and ABTS assays.
In both assays, punicalagin showed significantly higher antioxidant activity than PRE when at the
same concentration as punicalagin, although addition of Zn (II) did not cause any significant changes
in the ROS scavenging capacities of punicalagin and PRE, probably due to the stability of the Zn
(II) ion in respect of redox reactions. Seeram et al. [47] found that pomegranate juice had higher
antioxidant activity than punicalagin when they used the same concentrations of pomegranate juice
and punicalagin and suggested a synergistic/additive activity of polyphenols than only one compound
for this result. However, it is very difficult to assess the antioxidant activity, using a single method,
since it can provide only basic information about antioxidant activity but using different methods
can give more detail. There could be differences between the results because of extract and sample
preparation, selection of endpoints and expression of results [48]. That said, it has been suggested
that there is a correlation between the phenolic contents and antioxidant properties of PRE, with the
most abundant polyphenol being punicalagin [46,49,50]. Thus, as the antioxidant assay data in this
study provided a dose-dependent response, this may further imply that polyphenols are responsible
for the antioxidant activity in PRE and punicalagin. Indeed, punicalagin showed higher antioxidant
activity than PRE at the same concentrations in both DPPH and ABTS assays, as PRE contains a range
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of non-phenolic compounds. Therefore, it may be suggested that the antioxidant activity of PRE could
be attributed to its punicalagin content, in line with previous findings [18,40–43,50].
Assessment of PRE and punicalagin effects on human gingival fibroblasts alone and in combination
with Zn (II) showed no stimulation of fibroblast proliferation over the 72 h culture period. In contrast,
PRE and punicalagin significantly reduced fibroblast viability at high concentrations (100 µg/mL
and 10 µg/mL respectively) and when applied with Zn (II). Similar findings have been reported
with other natural compounds and extracts, such as propolis, where despite its antimicrobial and
antioxidant properties mediated through its polyphenol constituents, it can promote significant
fibroblast cytotoxicity when co-administered with Zn (II) [51]. Furthermore, numerous studies have
demonstrated the anti-proliferative or cytotoxic activities of PRE and punicalagin against a wide
range of cancer cell types [22,52–55] and fibroblasts [56]. Similarly, although many studies have
shown the stimulatory effects of Zn (II) on keratinocyte proliferation [29,31], negligible or inhibitory
effects on fibroblast proliferative responses have been identified for Zn (II) [57,58]. However, such
responses are likely to be concentration dependent, as fibroblasts are reported as being resistant to Zn
(II) cytotoxicity <500 mM [59], as evident here.
Further studies evaluated PRE and punicalagin effects on gingival fibroblast migration and wound
repopulation alone and in combination with Zn (II), via the analysis of relevant parameters including
cell migration speed, cell displacement, overall velocity and distance travelled, over 48 h in culture.
High concentrations of PRE (100 µg/mL) and punicalagin (10 µg/mL) significantly inhibited fibroblast
migration and wound repopulation, presumably as a consequence of the cytotoxic effects identified
above. However, lower PRE and punicalagin concentrations maintained or enhanced fibroblast
migration and wound repopulation, equivalent to untreated controls. Furthermore, despite Zn (II)
alone exerting no effects on fibroblast wound repopulation, 0.1 µg/mL punicalagin combined with
0.1 mM Zn (II) induced significant increases in cell speed and distance travelled, versus untreated
controls; whilst 0.1 mM Zn (II) supplementation also attenuated the inhibitory effects of punicalagin
(10 µg/mL) on cell speed. Such stimulatory effects on cell migration are significant, as previous
studies have mostly described the inhibitory effects of PRE and punicalagin on cell motility/invasion,
for instance, in cancer cells [22,52,53]. However, as Zn (II) and Zn-containing compounds can
significantly enhance fibroblast migration and wound closure in vitro and in vivo [29,31,60], Zn (II)
may actually be the key mediator of the increased fibroblast migratory responses identified herein.
Fibroblasts play a pivotal role in mediating wound healing responses, from initial cellular
migration, proliferation and cytokine/growth factor production to subsequent extracellular matrix
(ECM) synthesis/remodeling, wound contraction and closure. Thus, as wound repopulation is
acknowledged to be dependent on the induction of both migratory and proliferative responses [61],
the data presented herein would suggest that punicalagin and Zn (II) primarily promote oral fibroblast
migration, rather than proliferation, in light of the absence of stimulated fibroblast proliferative
responses induced by these concentrations alone or in combination. However, although oral and
dermal wounds proceed through similar stages of healing, oral wounds are well- characterized
by minimal inflammatory and angiogenic responses, rapid healing and minimal scar formation; unlike
dermal wounds [5,6], with such superior healing responses attributed to the specialized genotypic
and phenotypic properties of fibroblasts residing within oral tissues. In contrast, in non-healing skin
wounds, such cellular responses are impaired, leading to failed wound closure [62]. Thus, fibroblast
viability and induced proliferative and migratory responses are key events in normal repair processes,
although differences in the responses of oral and dermal fibroblasts to specific PRE or punicalagin
concentrations may be a consequence of the well-established differences in proliferative and migratory
capabilities which exist between these distinct fibroblast populations [6].
Although the positive dermal wound healing activities of PRE and punicalagin have been
recognized for some time [19–24], our findings are the first to report on the potential wound healing
benefits of punicalagin in combination with Zn (II) to oral wounds caused by periodontal disease
or trauma, in terms of alleviating ROS levels and oxidative stress and by stimulating gingival
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fibroblast migration. Whereas such particular antioxidant and pro-migratory responses could benefit
gingival repair processes, it remains to be determined whether PRE or punicalagin alone or with
Zn (II) supplementation possess any bactericidal, bacteriostatic or anti-biofilm properties versus the
pathogenic Gram-negative bacterial species commonly associated with the initiation and progression
of periodontal disease, such as Porphyromonas gingivalis [63], as established with microflora from
other clinical situations [16,25,40,46]. However, such antimicrobial properties are currently under
investigation. As uncontrolled biofilms initiate and sustain the inflammatory and resident connective
tissue cell destruction in periodontal tissues, the therapeutic limitation or eradication of microbial
biofilm accumulation by PRE or punicalagin would undoubtedly help inhibit the development and
progression of periodontal disease evoking further tissue reparative responses.
5. Conclusions
Although pomegranate (Punica granatum) extracts and its bioactive constituents, such as
punicalagin, have been used since ancient times to treat a broad range of diseases and conditions, only
now have studies begun to assess its therapeutic potential for the treatment of wounds within the oral
cavity, such as those manifested during periodontal disease or trauma. Both PRE and punicalagin were
shown to possess potent antioxidant capabilities, whilst punicalagin combined with Zn (II) further
induced human gingival fibroblast migration and wound repopulation responses, but exerted no
stimulatory effects on fibroblast proliferation. Therefore, purified punicalagin in combination with
Zn (II) may offer potential benefits as a natural compound-based therapy, aiding wound healing
mechanisms within the oral cavity.
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